QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Aflibercept Biosimilar, VEGF-Trap Biology, Retinal Disease and Product Pharmacovigilance

Test your understanding of the concepts covered by Aflibercept Biosimilar: VEGF-Trap Biology, Retinal Disease, Biosimilarity and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the main pharmacovigilance value of recording the exact administered brand and batch number for an aflibercept case?

It proves that the biosimilar is clinically different from the reference product It allows assessment of whether an event reflects a class effect, product-specific issue, batch problem or unrelated disease It replaces the need to document the clinical phenotype It is relevant only for reimbursement and not for safety surveillance

Question 2 of 10 What is the primary regulatory rationale for extrapolating a biosimilar's use to multiple reference-product indications?

All retinal diseases are clinically identical A single clinical trial automatically proves efficacy in every disease Strong analytical, functional and mechanistic similarity can reduce the need to repeat large efficacy trials in every indication Extrapolation means that no evidence exists for the biosimilar

Question 3 of 10 Which finding most strongly supports an acute volume-related intraocular pressure mechanism after injection?

Visual blurring beginning immediately, with IOP of 48 mmHg that falls after treatment Gradual retinal haemorrhage months after treatment with normal IOP Delayed fever and hypopyon with positive vitreous culture Bilateral myocardial infarction after repeated injections

Question 4 of 10 Why should a stroke occurring after intravitreal aflibercept not be attributed solely on the basis of temporal association?

Intravitreal treatment cannot have any systemic effects The treated populations may have substantial baseline vascular risk and VEGF inhibition has a potential class concern, requiring assessment of alternatives Stroke is unrelated to vascular biology A stroke can only be associated with an ocular adverse event

Question 5 of 10 Why is the IgG1 Fc component of aflibercept relevant to understanding the product?

It shows that aflibercept is a conventional anti-VEGF monoclonal antibody It is part of the fusion-protein architecture and contributes to the biological product's molecular format It converts the product into a small molecule suitable for oral administration It eliminates all potential for immunogenicity

Question 6 of 10 Which set of information would be most valuable for assessing a reported myocardial infarction after intravitreal treatment?

Only the product's generic name Baseline cardiovascular disease, timing relative to injection, antithrombotic therapy and other VEGF-inhibitor exposure Only the patient's visual acuity before injection The colour and packaging design of the syringe

Question 7 of 10 A patient reports visual loss after a first Pavblu injection following two years of reference aflibercept. Which conclusion is most professionally justified at the initial assessment stage?

The switch caused the event because it occurred after the switch The biosimilar cannot be involved because biosimilarity was established The event requires assessment of disease activity, procedure-related risks, objective findings, product identity and alternative causes The report should be dismissed as a nocebo effect

Question 8 of 10 Why should endophthalmitis, sterile intraocular inflammation and retinal vasculitis not be pooled into a single generic 'eye inflammation' category during signal review?

They have different likely mechanisms, diagnostic criteria and control measures They always occur in different patient populations Pooling is required for all biological medicines They are administrative terms with no clinical significance

Question 9 of 10 What is the most appropriate interpretation of a newly reported postmarketing safety item added to the reference-product information?

It is automatically irrelevant to the biosimilar because the products are not identical It may be relevant to biosimilar pharmacovigilance and should be considered alongside current product information and scientific evidence It proves that the biosimilar caused the event It eliminates the need for spontaneous reporting of the event

Question 10 of 10 A patient with neovascular AMD develops a new haemorrhagic lesion beneath the macula. Which disease mechanism is most relevant?

Pathological choroidal neovascularisation with leakage from fragile abnormal vessels Acute volume-related elevation of intraocular pressure A procedure-related retinal tear caused by the injection needle Systemic inhibition of platelet production by aflibercept

Knowledge Assessment: Aflibercept Biosimilar, VEGF-Trap Biology, Retinal Disease and Product Pharmacovigilance

Cookie Settings